Regeneron Pharmaceuticals Inc. Stock
Regeneron Pharmaceuticals, Inc. is a biotechnology company that is engaged in the discovery, development, and commercialization of medicines for the treatment of serious medical conditions. The company's products include EYLEA, a treatment for wet age-related macular degeneration and diabetic macular edema; Dupixent, a treatment for atopic dermatitis and asthma; and Libtayo, a treatment for certain types of cancer. Regeneron also has a strong focus on research and development, with a pipeline of potential new treatments for a variety of diseases. The company is headquartered in Tarrytown, New York and trades on the NASDAQ stock exchange under the symbol REGN.
Pros and Cons of Regeneron Pharmaceuticals Inc. in the next few years
Performance of Regeneron Pharmaceuticals Inc. vs. its peers
|Regeneron Pharmaceuticals Inc.||-0.380%||4.206%||1.561%||7.670%||16.025%||90.111%||137.986%|
The biotech sector and its popular ETF, the iShares Biotechnology ETF (NASDAQ: IBB), has lagged the overall market during the year. However, in recent weeks, the sector has enjoyed a significant
Regeneron Pharmaceuticals (NASDAQ: REGN) is a top pharmaceutical company with many promising assets in its portfolio. Its diverse business has enabled the business to grow over the years. In the
Biotech giant Regeneron (NASDAQ: REGN) and streaming specialist Roku (NASDAQ: ROKU) have been solid performers for most of the year, but both stocks recently jumped following their third-quarter